Jade Biosciences Inc. (JBIO)
NASDAQ: JBIO
· Real-Time Price · USD
7.04
-0.28 (-3.83%)
At close: May 23, 2025, 3:59 PM
7.03
-0.14%
After-hours: May 23, 2025, 04:00 PM EDT
Company Description
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases.
Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy.
JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026.
The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Jade Biosciences Inc.
| Country | United States |
| IPO Date | Apr 29, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Tom Frohlich |
Contact Details
Address: No Address available Waltham, United States | |
| Website | https://jadebiosciences.com/ |
Stock Details
| Ticker Symbol | JBIO |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 008064206 |
| ISIN Number | US0080642061 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Tom Frohlich | Chief Executive Officer & Director |
| Amy Sullivan | Senior Vice President of Development Operations |
| Dr. Andrew James King D.V.M., Ph.D. | Chief Scientific Officer & Head of R&D |
| Dr. Hetal Kocinsky M.D. | Chief Medical Officer |
| Dr. Jason Wright Ph.D. | Senior Vice President, Chemistry, Manufacturing & Controls |
| Elizabeth Balta | General Counsel & Corporate Secretary |
| Jonathan Quick | Senior Vice President of Finance |
| Lori Stewart | Senior Vice President of People |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality |